The metabolic syndrome and neuropathy: Therapeutic challenges and opportunities

Annals of Neurology - Tập 74 Số 3 - Trang 397-403 - 2013
Brian C. Callaghan1, Eva L. Feldman2
1Department of Neurology, University of Michigan, Ann Arbor, MI
2University of Michigan, Department of Neurology, Ann Arbor, MI

Tóm tắt

The metabolic syndrome and neuropathy are common conditions, especially in the elderly, that are associated with significant morbidity. Furthermore, the metabolic syndrome is reaching epidemic proportions across the world. Current evidence supports the association of the metabolic syndrome and its individual components with neuropathy. Several clinical trials have demonstrated that treating hyperglycemia, a component of the metabolic syndrome, has a significant effect on reducing the incidence of neuropathy in those with type 1 diabetes. However, glucose control has only a marginal effect on preventing neuropathy in those with type 2 diabetes, suggesting that other factors may be driving nerve injury in these patients. Emerging evidence supports the metabolic syndrome as including risk factors for neuropathy. Interventions exist for treatment of all of the metabolic syndrome components, but only glucose control has strong evidence to support its use and is widely employed. Our understanding of the biology of metabolic nerve injury has rapidly expanded over the past several years. Mechanisms of injury include fatty deposition in nerves, extracellular protein glycation, mitochondrial dysfunction, and oxidative stress. Additionally, the activation of counter‐regulatory signaling pathways leads to chronic metabolic inflammation. Medications that target these signaling pathways are being used for a variety of diseases and are intriguing therapeutic agents for future neuropathy clinical trials. As we move forward, we need to expand our understanding of the association between the metabolic syndrome and neuropathy by addressing limitations of previous studies. Just as importantly, we must continue to investigate the pathophysiology of metabolically induced nerve injury. Ann Neurol 2013;74:397–403

Từ khóa


Tài liệu tham khảo

10.1056/NEJMoa055643

10.1016/S0140-6736(10)62037-5

10.1126/science.1230720

10.1001/jama.287.3.356

10.2337/diacare.28.11.2745

10.1016/j.ecl.2004.03.005

10.1186/1471-2458-10-246

10.1016/j.metabol.2009.04.008

10.1212/WNL.41.8.1315

10.1212/WNL.43.6.1115

10.2337/diacare.27.7.1591

10.2337/dc11-1108

10.1111/j.1464-5491.2004.01271.x

10.1016/S0168-8227(99)00112-6

10.1097/MAO.0b013e3181f2f035

Margolis DJ, 2011, Incidence of diabetic foot ulcer and lower extremity amputation among Medicare beneficiaries, 2006 to 2008, Data Points, 2

10.1016/j.diabet.2008.11.004

10.1111/jdi.12042

10.2337/diacare.28.7.1649

10.1111/j.1365-2362.1994.tb02379.x

10.1056/NEJMoa032782

Callaghan BC, 2012, Enhanced glucose control for preventing and treating diabetic neuropathy, Cochrane Database Syst Rev, 6, CD007543

10.1093/oxfordjournals.aje.a115547

10.1002/mus.1137

10.2337/diacare.24.8.1448

10.2337/dc06-0224

10.2337/dc06-0942

10.1111/j.1464-5491.2004.01124.x

10.1007/s001250100615

10.2337/db08-1771

10.1016/j.jns.2008.06.005

10.1126/science.1230721

10.1111/j.1529-8027.2012.00389.x

10.1530/JOE-12-0356

10.1111/j.1529-8027.2009.00237.x

10.1210/en.2006-0073

10.1038/nrneurol.2011.137

10.1016/j.expneurol.2012.11.001

10.1146/annurev-physiol-021909-135846

10.1038/nm.2851

10.1016/j.cell.2012.02.017

10.1016/j.nbd.2011.08.011

10.1210/jc.2008-2385

10.2337/dc08-2011

10.1152/jn.01123.2010

10.1002/ana.410380607

Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), 1998, UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837

10.1056/NEJMoa0808431

10.1016/S0140-6736(10)60576-4

10.1056/NEJMoa012512

10.1016/j.pneurobio.2012.06.003

10.4155/fmc.13.34

10.1182/blood-2011-07-366633

10.1074/jbc.M110.199737

10.4161/cc.21262

10.1172/JCI64099

Vinayak S, 2013, mTOR inhibitors in the treatment of breast cancer, Oncology (Williston Park), 27, 38

10.1158/0008-5472.CAN-10-1769

10.1016/j.cmet.2010.03.014

10.1517/13543784.2011.575359

10.1038/jcbfm.2009.240

10.1345/aph.1M483

10.7326/0003-4819-152-6-201003160-00004

10.1016/S1474-4422(12)70065-0

10.1097/WCO.0b013e328357a797

10.1016/S1474-4422(12)70065-0

Thông tin
Thông tin xuất bản

Annals of Neurology

Tập 74 Số 3

397-403

Thông tin tác giả